<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349619</url>
  </required_header>
  <id_info>
    <org_study_id>10/2017</org_study_id>
    <nct_id>NCT03349619</nct_id>
  </id_info>
  <brief_title>Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis</brief_title>
  <acronym>RENIM</acronym>
  <official_title>ReNIM Study - Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing Nasal Interleukin-5 (IL-5) Measurements in Children With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, randomized, placebo-controlled study to investigate the effect of Resveratrol
      plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) for nostril three times/day for 4
      weeks, in comparison with placebo, in reducing nasal interleukin-5 (IL-5) in children with
      Allergic Rhinitis (AR).

      Secondary objectives are to examine the effect of resveratrol plus carboxymethyl-β-glucan, in
      comparison with placebo, on subjective parameters, i.e. symptom scores, visual analogue
      scales for rhinitis, quality of life and quality of sleep, and the effect on objective
      parameters, i.e. nasal nitric oxide (nNO) levels, nasal cytology and acoustic rhinometry.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal Interleukin-5 (IL-5)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change in IL-5 level from baseline to the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total 5 Symptom Score (T5SS)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change in T5SS score from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for Rhinitis (VAS)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change in VAS score from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change in PRQLQ score from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change in PSQI score from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Exhaled Nitric Oxide (nNO)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change of nNO from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Cytology</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change in nasal cytology counts from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acoustic Rhinometry: Minimal Cross-sectional Area (MCA)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change of MCA from baseline to the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acoustic Rhinometry: Nasal Volume from the first 5 cm from the nostril (V.0-5)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change of V.0-5 from baseline to the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Resveratrol plus Carboxymethyl-β-Glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol plus Carboxymethyl-β-Glucan</intervention_name>
    <description>Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks</description>
    <arm_group_label>Resveratrol plus Carboxymethyl-β-Glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of AR in the previous year;

          -  positive skin prick test to seasonal allergens.

        Exclusion Criteria:

          -  acute upper respiratory infections in the last 4 weeks;

          -  lifetime history of asthma (doctor diagnosis);

          -  use of nasal or oral corticosteroids, nasal or oral decongestants, antihistamines in
             the last 4 weeks;

          -  anatomic nasal defects (ie, septum deviation), or nasal polyps;

          -  active smoker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefania La Grutta, Ph.D.</last_name>
    <phone>0916809680</phone>
    <email>stefania.lagrutta@ibim.cnr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanni Viegi, FERS</last_name>
    <phone>0916809501</phone>
    <email>giovanni.viegi@ibim.cnr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Biomedicine and Molecular Immunology (IBIM) - National Research Council of Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania La Grutta, Ph.D.</last_name>
      <phone>+390916809680</phone>
      <email>stefania.lagrutta@ibim.cnr.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Viegi, FERS</last_name>
      <phone>+390916809501</phone>
      <email>giovanni.viegi@ibim.cnr.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy</investigator_affiliation>
    <investigator_full_name>Stefania La Grutta, MD</investigator_full_name>
    <investigator_title>Ph.D. Senior Researcher. Coordinator of Pediatric Allergy and Asthma Research Group. Institute of Biomedicine and Molecular Immunology, IBIM, National Research Council of Palermo, Italy.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

